Journal Home
Search for

Volume 90, Issue 6, Pages 2031-2055 (December 2008)


View previous. 3 of 60 View next.

Reproductive organ transplantation: advances and controversies

Mohamed A. Bedaiwy, M.D., Ph.D.a, Ahmed Y. Shahin, M.D.b, Tommaso Falcone, M.D.aCorresponding Author Informationemail address

Received 5 August 2008; received in revised form 5 August 2008; accepted 5 August 2008. published online 20 October 2008.

Objective

To review the advances and controversies in the field of reproductive organ transplantation.

Result(s)

Although many cancer treatments can damage female reproductive organs, leading to temporary or permanent infertility, recent advances in cancer management have translated into improved patient survival, making preservation of reproductive function a more important priority than ever before. Reproductive organ transplantation represents a new potential treatment for patients facing infertility as a result of cancer treatment. Pregnancies have now been reported from several centers after transplanting fresh and frozen ovarian tissue pieces. The longevity of the graft and its potential long-term complications are unknown. However, it seems clear that the ovarian tissue graft has a shortened life span. Allogeneic reproductive organ transplants are under investigation. Patients must take immunosuppressive medications following heterologus transplantation, and these medications can cause adverse side effects. The effects on the fetus are largely unknown.

Conclusion(s)

Despite the recent biologic and clinical advances, reproductive organ transplantation remains experimental and controversial.

a Department of Obstetrics–Gynecology, The Cleveland Clinic Foundation, Cleveland, Ohio

b Department of Obstetrics and Gynecology, Women's Health Centre, Assiut University, Assiut City, Egypt

Corresponding Author InformationReprint requests: Tommaso Falcone, M.D., Department of Obstetrics and Gynecology, A81, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195 (FAX: 216-445-5526).

 M.A.B. has nothing to disclose. A.Y.S. has nothing to disclose. T.F. has nothing to disclose.

PII: S0015-0282(08)03306-2

doi:10.1016/j.fertnstert.2008.08.009


View previous. 3 of 60 View next.